================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 15, 2007
---------------------------------
Date of Report
(Date of earliest event reported)
ZYMOGENETICS, INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Washington 000-33489 91-1144498
---------------------------- ----------- -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File No.) Identification No.)
1201 Eastlake Avenue East, Seattle, Washington 98102-3702
------------------------------------------------------------
(Address of Principal Executive Offices, including Zip Code)
(206) 442-6600
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 2.02. Results of Operations and Financial Condition.
On February 15, 2007, ZymoGenetics, Inc. (the "Company") issued a press release
announcing its financial results for the fourth quarter and year ended December
31, 2006. The full text of the press release is set forth in Exhibit 99.1
attached hereto. The press release should be read in conjunction with the note
regarding forward-looking statements, which is included in the text of the press
release.
The information in this Current Report on Form 8-K, including the exhibits, will
not be treated as "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section. This information will not be incorporated by
reference into any filing under the Securities Act of 1933, or into another
filing under the Exchange Act, unless that filing expressly incorporates this
information by reference.
Item 9.01. Financial Statements and Exhibits.
(d) 99.1 Press Release dated February 15, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZYMOGENETICS, INC.
Dated: February 16, 2007 By /s/ James A. Johnson
-----------------------
James A. Johnson
Senior Vice President,
Chief Financial Officer
Exhibit Index
99.1 Press Release issued February 15, 2007